Ardent Health Reports Strong Q1 Results with 26% Adjusted EBITDA Growth; Reaffirms Full-Year Guidance
Summary
Ardent Health, Inc. announced strong first-quarter 2026 financial results, including a 7.0% increase in total revenue and a 26.3% rise in Adjusted EBITDA, while reaffirming its full-year guidance.
Key Events
-
Strong Q1 Financial Performance
Total revenue increased 7.0% year-over-year to $1.60 billion, and Adjusted EBITDA grew 26.3% year-over-year to $124 million for the first quarter ended March 31, 2026.
-
Full-Year Guidance Reaffirmed
The company reaffirmed its full-year 2026 financial guidance, projecting total revenue between $6,400 million and $6,700 million and Adjusted EBITDA between $485 million and $535 million.
-
Operational Growth Despite Headwinds
Adjusted admissions increased by 2.0% and total surgeries grew by 1.2% year-over-year, despite a slight decrease in overall admissions attributed to severe weather and a lighter respiratory season.
Analysis
Ardent Health, Inc. delivered a robust first quarter, marked by significant growth in Adjusted EBITDA and revenue, which signals strong operational execution. The reaffirmation of full-year guidance, despite some transient seasonal volume impacts, indicates management's confidence in sustained performance. This positive financial update, following closely on the heels of a Reuters report, provides investors with detailed confirmation of the company's solid start to the year and its outlook.
At the time of this filing, ARDT was trading at $10.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $8.07 to $15.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.